Marco Gutierrez Md And Associates

CLIA Laboratory Citation Details

3
Total Citations
16
Total Deficiencyies
9
Unique D-Tags
CMS Certification Number 45D1052653
Address 5148 N 10th St, Mcallen, TX, 78504
City Mcallen
State TX
Zip Code78504
Phone956 683-8700
Lab DirectorMARCO GUTIERREZ

Citation History (3 surveys)

Survey - June 2, 2026

Survey Type: Standard

Survey Event ID: 5MLL11

Deficiency Tags: D5469 D6020 D5441 D5785

Summary:

Summary Statement of Deficiencies D5441 CONTROL PROCEDURES CFR(s): 493.1256(a)(b)(c)(g) (a) For each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process. (b) The laboratory must establish the number, type, and frequency of testing control materials using, if applicable, the performance specifications verified or established by the laboratory as specified in 493.1253(b)(3). (c) The control procedures must-- (c)(1) Detect immediate errors that occur due to test system failure, adverse environmental conditions, and operator performance. (c)(2) Monitor over time the accuracy and precision of test performance that may be influenced by changes in test system performance and environmental conditions, and variance in operator performance. This STANDARD is not met as evidenced by: Based on review of the laboratory's quality control records for the DCA Vantage microalbumin/creatinine assay from June 2024 to June 2026, and staff interview, the laboratory failed to have documentation of monitoring quality control values over time for 3 of 3 lots. The findings included: 1. A review of the laboratory's DCA Vantage control records from June 2024 to June 2026 identified the laboratory utilized the following 3 lots: 0063 0064 0066 2. The laboratory failed to have documentation of monitoring control values over time to detect shifts and trends from June 2024 to June 2026. 3. The technical consultant confirmed the findings in an interview conducted on 06/02/2026 at 1130 hours in the conference room. D5469 CONTROL PROCEDURES CFR(s): 493.1256(d)(10)(g) (d)(10) Establish or verify the criteria for acceptability of all control materials. (d)(10) (i) When control materials providing quantitative results are used, statistical parameters (for example, mean and standard deviation) for each batch and lot number Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- of control materials must be defined and available. (d)(10)(ii) The laboratory may use the stated value of a commercially assayed control material provided the stated value is for the methodology and instrumentation employed by the laboratory and is verified by the laboratory. (d)(10)(iii) Statistical parameters for unassayed control materials must be established over time by the laboratory through concurrent testing of control materials having previously determined statistical parameters. This STANDARD is not met as evidenced by: Based on review of the laboratory's Medonic M-series hematology quality control records from September 2025 to March 2026, and staff interview, the laboratory failed to have documentation of verifying 2 of 3 new lots of control material prior to placing them into use. The findings included: 1. A review of the laboratory's quality control records for the Medonic M-series hematology analyzer from September 2025 to March 2026 determined the the laboratory failed to have documentation of verifying the following 2 of 3 lots of control material prior to placing them into use: Lot: 22508 Lot: 22511 2. The technical consultant confirmed the findings in an interview conducted on 06/02/2026 at 1045 hours in the conference room. D5785

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 6, 2022

Survey Type: Standard

Survey Event ID: E5II11

Deficiency Tags: D5775 D2007 D5775 D0000

Summary:

Summary Statement of Deficiencies D0000 The laboratory was surveyed on April 6, 2022 and found to be in compliance with the conditions of participation found in the CLIA regulations at 42 CFR 493 and recertification is recommended. D2007 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The samples must be examined or tested with the laboratory's regular patient workload by personnel who routinely perform the testing in the laboratory, using the laboratory's routine methods This STANDARD is not met as evidenced by: Review of the laboratory's American Proficiency Institute (API) proficiency testing (PT) records for 2021 (events 1, 2, and 3) and 2022 (event 1), review of personnel files, and interview with laboratory personnel, the laboratory failed to ensure 1 of 2 testing personnel participated in proficiency testing for Hematology in 2021. The findings were: 1. Review of the laboratory's API Attestation records for Hematology 2021 (events 1, 2, and 3) found testing personnel #1 (as listed on Form CMS 209) performed testing each 3 of 3 events. 2. Review of the laboratory's personnel records found testing personnel #2 (as listed on Form CMS 209) has been testing since June 17, 2020. Therefore, testing personnel #2 should have participated in the 2021 proficiency testing events for Hematology. 3. The laboratory was asked to provide documentation that would exclude testing personnel #2 (as listed on Form CMS 209) from participating in any of the three Hematology testing events. No documentation was provided. 4. In an interview on April 6, 2021 at 09:51 hours in the break room with Testing Personnel #1 (as listed on Form CMS 209) 2021), he stated that he would try to do them as they came in so they did not get behind. This confirmed the findings. D5775 COMPARISON OF TEST RESULTS Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- CFR(s): 493.1281(a)(c) (a) If a laboratory performs the same test using different methodologies or instruments, or performs the same test at multiple testing sites, the laboratory must have a system that twice a year evaluates and defines the relationship between test results using the different methodologies, instruments, or testing sites. (c) The laboratory must document all test result comparison activities. This STANDARD is not met as evidenced by: Based on review of laboratory instrument records, and interview with laboratory personnel, the laboratory failed to at least twice annually compare the relationship between 2 of 2 Siemens DCA Vantage analyzers used to perform Microalbumin and Creatinine in 2021. The findings included: 1. Review of the laboratory's twice annual instrument to instrument correlation records for 2020 and 2021 found the laboratory failed to compare the relationship between 2 of 2 DCA Vantage analyzers used to perform Microalbumin and Creatinine in 2021. a. 2020 records found the laboratory performed the instrument to instrument correlation studies in July 2020 and December 2020. 2. The laboratory was asked to provide documentation of performing the required instrument to instrument correlation studies at least twice annually in 2021. No documentation was provided. 3. In an interview on April 6, 2022 at 12:20 hours in the break room Testing Personnel #1 (as listed on Form CMS 209) stated he thought the technical consultant had told him he no longer had to do that. This confirmed the findings. Key: CMS - Centers for Medicare and Medicaid Services. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - December 9, 2020

Survey Type: Standard

Survey Event ID: TPR111

Deficiency Tags: D0000 D3033 D5441 D5447 D0000 D3033 D5441 D5447

Summary:

Summary Statement of Deficiencies D0000 Noted deficiencies and plans of correction were discussed with the laboratory representative at the entrance and exit conferences. The facility representative was given an opportunity to provide evidence of compliance with the noted deficiencies, and no such evidence was provided prior to survey exit. The facility was found to be in compliance with applicable Conditions of Participation in the CLIA program, and recertification is recommended. Note: The CMS-2567 (Statement of Deficiencies) is an official, legal document. All information must remain unchanged except for entering the

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access